Ricam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ricam

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, Oral solution, Syrup
Pharmacological class Second-Generation Antihistamine
General purpose Management of systemic allergic responses
Origin Synthetic metabolite of Hydroxyzine

Ricam is a commercial brand of a pharmaceutical preparation containing Cetirizine Hydrochloride as its sole active ingredient. It is a single monotherapy product classified as a second-generation antihistamine, functioning primarily to mitigate the body’s adverse reaction to histamine (a key chemical mediator released during an allergic event). The drug is primarily marketed for use in both adults and children, often holding an Over-The-Counter (OTC) status, depending on the specific country's regulatory framework.


What Type of Medicine is Ricam?

Ricam is fundamentally a selective peripheral H1-receptor antagonist belonging to the pharmacological class of antihistamines. The active compound, Cetirizine, is a synthetic compound that originated as the carboxylic acid metabolite of Hydroxyzine.

The drug is formulated for oral (systemic administration) and is available in multiple dosage forms, including the standard tablet, oral solution, and syrup. The availability of liquid forms, such as the oral solution, specifically targets the ease of administration for the pediatric patient group.


How is Ricam Classified Among Allergy Medications?

Ricam is classified as a modern, targeted allergy medication because its core mechanism principle involves selective histamine blockade outside the central nervous system. This peripheral selectivity is the key feature distinguishing second-generation compounds; they primarily target H1 receptors responsible for allergic symptoms in the body’s tissues. This approach is designed for achieving effective systemic relief with a less sedating profile compared to first-generation alternatives. The classification confirms that Ricam is intended to be a focused intervention against histamine-mediated processes.


What is the General Purpose of Ricam?

The general therapeutic purpose of Ricam is to manage and mitigate the physiological distress and discomfort that arise from unwanted systemic allergic reactions. By competitively blocking the H1 receptors, the drug supports the body's tissues in returning to a state of normalcy when challenged by an allergen. This makes it a crucial systemic agent for general allergy treatment, addressing the body's overreaction without detailing specific ailments or conditions.

Regulatory References

  1. NIH National Library of Medicine

What side effects are possible with Ricam?

Possible Side Effects and Safety Information

The safety profile of Ricam (Cetirizine Hydrochloride) is formally documented by regulatory authorities, classifying potential adverse reactions by both their observed frequency and the affected body system. This classification provides a neutral, regulatory perspective on the medicine's risk profile.

Officially documented side effects are categorized into several frequency bands, defining how often they may occur in clinical use. Common reactions, reported in regulatory labeling, include effects such as somnolence, fatigue, headache, dizziness, dry mouth, and nausea. These are the most frequently observed events. Reactions classified as Uncommon include agitation, paresthesia, and skin reactions like pruritus (itching) and rash.

Less frequently, the label documents Rare events, which involve systemic effects such as hypersensitivity reactions, tachycardia, convulsions, and abnormal hepatic function (elevated liver enzymes). Very Rare events include serious reactions like anaphylactic shock, angioneurotic oedema, and effects on the blood (thrombocytopenia).

The safety profile includes specific limitations. Caution is documented for patients with a predisposition to urinary retention or a history of epilepsy/convulsions. Furthermore, the regulatory labeling specifies that the medicine is contraindicated in individuals with severe renal impairment (kidney function classified as creatinine clearance less than 10 mL/min). A dose adjustment is required for patients with moderate to severe renal impairment. Regulatory documents also note that intense itching and hives may occur upon discontinuation of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the manifestations and required emergency actions for an overdosage of Ricam (Cetirizine Hydrochloride). Symptoms are typically reported following the intake of a dose at least five times the recommended daily amount.


Documented Overdose Manifestations

Overdosage primarily affects the Central Nervous System (CNS) and may present with effects suggestive of an anticholinergic mechanism. Clinical signs documented in regulatory labeling include somnolence (drowsiness), sedation, stupor, confusion, and fatigue. Other documented signs include tachycardia (rapid heartbeat), urinary retention, mydriasis (pupil dilation), and diarrhoea. In children aged 6 to 11 years, specific manifestations have been assessed following an overdosage.


Required Emergency Actions

Immediate medical attention or contacting a Poison Control Center is required if an overdose is suspected. Urgent medical services must be contacted immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

There is no known specific antidote for Cetirizine. Management involves symptomatic or supportive treatment. Procedures such as gastric lavage may be considered shortly after ingestion, and cardiac monitoring may be necessary in cases of large overdoses.

Therapeutic Uses of Ricam

What Ricam Treats: Main Uses and Benefits

This medication is commonly used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. This medication is used for managing symptoms related to inflammatory or irritative states, such as those associated with osteoarthritis and rheumatoid arthritis. By moderating the intensity of these manifestations, it provides support that helps ease the overall symptom burden and contributes to greater comfort during periods of heightened symptoms.

Ricam is considered relevant for easing symptom clusters that may become intense or disruptive, such as joint and muscle stiffness. It supports the handling of symptoms that interfere with daily comfort, offering symptomatic relief. This support is helpful in conditions characterized by periods of heightened symptoms and is applied in clinical settings that involve acute or unstable symptom patterns. This may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress when symptoms interfere with routine activities.


Quick Fact: Relevant for Inflammatory Symptoms

Eligibility and Restrictions for Use

Ricam (Cetirizine Hydrochloride) is subject to specific regulatory eligibility rules that define who is permitted to use the medicine and who must not use it.

Populations for whom use is Contraindicated

Use is strictly contraindicated for patients with a known hypersensitivity to Cetirizine, its parent compound Hydroxyzine, or any of the inactive ingredients. It is also contraindicated in patients with severe renal impairment defined by a creatinine clearance of less than 10 mL/min.

Age-Related Eligibility and Restrictions

Age Group Regulatory Status
Adults and Adolescents (ge 12 years) Permitted (Standard Use)
Children 6 to 11 years Permitted (Standard Use)
Children under 2 years Use not established or not recommended

Older adult patients (ge 65 years) may require conditional use due to the potential for reduced kidney function, necessitating regulatory caution.

Condition-Specific and Conditional Use

Patients with moderate or severe renal impairment (CrCL 10-50 mL/min) or hepatic impairment require conditional use as a reduced dose is necessary. Caution is advised in patients with predisposing factors for urinary retention or those with epilepsy due to specific documented risks. The medicine's use is not recommended for breastfeeding women, as the compound is excreted into human milk, and is also not recommended during pregnancy unless clearly needed.

What should I know about interactions with other medicines?

Ricam Interactions with other medicines and products

The official regulatory profile for Ricam (Cetirizine Hydrochloride) details interaction patterns based on pharmacodynamic additivity and specific pharmacokinetic changes.

Drug and Substance Interactions

Co-administration of Ricam with alcohol or other Central Nervous System (CNS) depressants (such as specific opioid medications or certain sleeping medications) may cause an additive reduction in alertness and further impairment of performance. This potential additive effect is a documented pharmacodynamic interaction.

A specific pharmacokinetic modification involves Theophylline: when Theophylline is co-administered at a dose of 400 mg once daily, it is documented to cause a 16% decrease in the clearance of Ricam, resulting in increased systemic plasma exposure. Ricam carries a low risk for metabolic interactions, as it is confirmed not a substrate of the CYP450 enzyme system. Nonetheless, regulatory information confirms the drug is a substrate of the P-glycoprotein efflux transporter.

Non-Drug and Population Considerations

Food intake does not alter the total extent of Ricam's systemic exposure but does cause a decrease in the rate of absorption, delaying the time required to reach peak concentration. No mandatory drug timing separation rules are listed in the primary regulatory documentation. Interaction risk is formally documented as heightened for patients with impaired renal function or impaired hepatic function. Reduced clearance in these populations leads to increased plasma exposure of Ricam, which can amplify the impact of any documented drug interactions.

Mechanism of Action

Enzyme-Mediated Signaling Modulation

Ricam acts as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These membrane-bound enzymes catalyze the conversion of arachidonic acid into various eicosanoids, including prostaglandins. This molecular interaction occurs at the enzyme's active site, preventing the initial chemical reaction in the cascade.


Modulation of Pathway Signaling Intensity

The inhibition of COX activity results in a systemic reduction in the biosynthesis and concentration of prostaglandins at the cellular and tissue level. Prostaglandins function as localized signaling mediators; their reduced availability leads to an altered level of basal pathway activity in systems sensitive to these mediators. This consequence is a direct modulation of the intensity of downstream signaling that typically propagates heightened physiological responses.

Dosage and Administration Information

Official Dosing and Administration

Ricam (Cetirizine Hydrochloride) is administered via the oral route, available as tablets, oral solution, or syrup, and the intravenous (IV) route for the injectable solution, typically reserved for acute episodes. The medication is used either for a short course for acute symptoms or as part of a longer maintenance plan.


Standard Dosage Regimens

The standard adult and adolescent dose (ages 12 and older) is 5 mg or 10 mg taken once daily, with the maximum recommended daily limit set at 10 mg.

For children, the regimen is based on age: those aged 6 to 11 years typically receive 5 mg twice daily or 10 mg once daily. Children 2 to 5 years old begin with 2.5 mg once daily, potentially increasing to 5 mg daily, taken either as a single dose or divided into 2.5 mg doses twice daily.


Administration Conditions and Adjustments

Oral formulations allow administration with or without food, as food does not significantly affect the extent of absorption. The 10 mg tablets are often scored to facilitate accurate division into a 5 mg dose when needed.

For the intravenous route, the 10 mg dose must be delivered as a controlled intravenous push over a 1 to 2 minute period. Usage is contingent upon the patient's renal function; a dose reduction to 5 mg once daily is required for adults diagnosed with moderate to severe kidney impairment, specifically where the creatinine clearance (CrCl) is below 50 mL/min.

Recent Clinical Evidence

Research evidence / Overview of studies for Ricam

The research base for Ricam, which contains Cetirizine, primarily consists of studies that was studied for defined time intervals in people experiencing allergic reactions. These studies, including Randomized Controlled Trials (RCTs) and comprehensive reviews, contributes to understanding how patients reported their experience and provides insight into short-term patterns in specific symptoms associated with histamine-mediated conditions.


Evidence for Managing Seasonal and Perennial Allergic Rhinitis

Clinical research was studied for Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR) using patient-reported outcomes describing perceived discomfort. These studies primarily evaluated measurements of classic upper respiratory allergic symptoms (like sneezing and runny nose) and associated Quality of Life measures. The findings describe patterns observed in the trials related to measurements of these symptoms. However, research exploring short-term symptom changes is most abundant, and comparative evidence against some other second-generation antihistamines remains limited.

Evidence for Managing Chronic Hives (Urticaria)

Ricam was evaluated in studies for its use in Chronic Urticaria (hives). These trials primarily monitored outcomes linked to inflammatory or irritative states and outcomes related to physical discomfort, evaluating measurements of itching and wheal severity. The evidence base is extensive; however, data for non-standard, higher dosages often involves smaller sample sizes, and follow-up durations were limited in these specific investigations.


Research in Special Populations and Limitations

The research describes that for certain indications, the medicine was evaluated in children as young as 6 months in the context of rhinitis and urticaria research. Conversely, for older patients (aged 65 years and older), research did not always include an adequate number of participants to explore whether symptom patterns varied in comparison to younger adults.

The majority of clinical trials examine short-term symptom patterns. There is limited information for long-term outcomes regarding the continuous use of the medicine for periods exceeding one year. This means that long-term effects are not fully established across the broader evidence base. Furthermore, data for certain groups are limited regarding comparative trials against all alternative therapeutic options.

Key Studies & References

  1. EAACI/GA²LEN/EuroGuiDerm guideline for the definition, classification, diagnosis and management of urticaria 2021

Frequently Asked Questions (FAQ)

Common questions about Ricam (FAQ)


Q: How long does it take for Ricam to start working after I take a dose?

Studies included in the official product information, the anti-histaminic effects of the active ingredient (cetirizine) were typically observed within one hour for a high percentage of participants. The time it takes for relief to begin can vary between individuals.


Q: What are the symptoms of an overdose of Ricam?

Regulatory documents state that symptoms following an overdose are often linked to effects on the central nervous system (CNS). These effects can include sedation, dizziness, or confusion. Other symptoms reported may include tachycardia (fast heart rate) and issues like urinary retention.


Q: Is Ricam safe for me to take if I'm pregnant?

Official information advises that caution should be exercised when considering the use of this medicine during pregnancy. While animal studies have not indicated direct harm to fetal development, clinical data on its use in pregnant individuals is limited. Individuals who are pregnant or planning to become pregnant are advised to consult a healthcare professional before use.


Q: Can I drive or operate machinery while on this medicine?

Official labeling warns that drowsiness may occur while taking Ricam, which could potentially impair mental alertness. The labeling emphasizes not exceeding the recommended dose, as this may increase the risk of this side effect. It is advised that individuals understand how the medication affects them before engaging in activities that require full mental focus, such as driving or operating machinery.


Q: Is this medicine safe to take long-term?

Official information indicates that data on the safety of Ricam for continuous use lasting longer than one year is limited. Official regulatory information notes that discontinuing the medicine after extended, long-term daily use has been associated with reports of a rebound effect involving severe and widespread itching that was not present prior to treatment.

How should Ricam be stored and disposed of?

How to Store and Dispose of Ricam

Ricam (Cetirizine Hydrochloride) must be stored and handled according to its official labeling to ensure product stability and safety.


Storage Requirements

  • Temperature: Store the medication at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to protect the product from excess heat and moisture and should be kept from freezing.
  • Packaging: Keep the medicine in its original container and ensure the cap is tightly closed to maintain container integrity.
  • Child Safety: The product must be stored securely out of the sight and reach of children to prevent accidental ingestion, as mandated by regulatory requirements.

Disposal Instructions

  • Official Disposal: Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist or healthcare professional for the proper disposal method, which typically involves utilizing an approved pharmaceutical take-back program or following local regulatory instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ricam found in:

A-Z Index: